Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Miaoshou Doctor Completes $73 Million C+ Round at $1 Billion Valuation

publication date: Jul 12, 2019

Miaoshou Doctor, an online/offline healthcare company headquartered in Beijing, completed a $72.8 million Series C+ financing round, led by Starquest Capital and including Sequoia Capital China along with other investors. Although the round was completed in January, it is now known that the round was priced at a better than $1 billion Unicorn valuation for Miaoshou. The company offers a chain of offline pharmacies, online links between doctors and patients, online healthcare consultation and O2O services. In the previous C round one year ago, Miaoshou raised $79.3 million, led by Tencent. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China